Ajanta Pharma Revenue vs. Book Value Per Share
| AJANTPHARM | 3,023 92.20 3.15% |
Total Revenue | First Reported 2014-06-30 | Previous Quarter 11.4 B | Current Value 11.9 B | Quarterly Volatility 2.4 B |
For Ajanta Pharma profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Ajanta Pharma to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Ajanta Pharma Limited utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Ajanta Pharma's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Ajanta Pharma Limited over time as well as its relative position and ranking within its peers.
Ajanta |
Ajanta Pharma Limited Book Value Per Share vs. Revenue Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Ajanta Pharma's current stock value. Our valuation model uses many indicators to compare Ajanta Pharma value to that of its competitors to determine the firm's financial worth. Ajanta Pharma Limited is the top company in revenue category among its peers. It also is number one stock in book value per share category among its peers . The ratio of Revenue to Book Value Per Share for Ajanta Pharma Limited is about 143,478,424 . As of now, Ajanta Pharma's Total Revenue is increasing as compared to previous years. Comparative valuation analysis is a catch-all model that can be used if you cannot value Ajanta Pharma by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Ajanta Pharma's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Ajanta Revenue vs. Competition
Ajanta Pharma Limited is the top company in revenue category among its peers. Market size based on revenue of Health Care industry is presently estimated at about 410.21 Billion. Ajanta Pharma retains roughly 42.09 Billion in revenue claiming about 10% of equities under Health Care industry.
Ajanta Book Value Per Share vs. Revenue
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Ajanta Pharma |
| = | 42.09 B |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
Ajanta Pharma |
| = | 293.33 X |
The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.
Ajanta Book Value Per Share Comparison
Ajanta Pharma is currently under evaluation in book value per share category among its peers.
Ajanta Pharma Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Ajanta Pharma, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Ajanta Pharma will eventually generate negative long term returns. The profitability progress is the general direction of Ajanta Pharma's change in net profit over the period of time. It can combine multiple indicators of Ajanta Pharma, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 2.3 B | 2.4 B | |
| Operating Income | 19.7 B | 20.7 B | |
| Income Before Tax | 11.1 B | 11.7 B | |
| Total Other Income Expense Net | -8.5 B | -8.1 B | |
| Net Income | 8.2 B | 4.2 B | |
| Income Tax Expense | 3 B | 3.1 B | |
| Net Income From Continuing Ops | 8.2 B | 5.6 B | |
| Net Income Applicable To Common Shares | 6.8 B | 5.2 B | |
| Interest Income | 277.1 M | 305.3 M | |
| Net Interest Income | -72.1 M | -75.7 M | |
| Change To Netincome | -680 M | -646 M |
Ajanta Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Ajanta Pharma. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Ajanta Pharma position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Ajanta Pharma's important profitability drivers and their relationship over time.
Use Ajanta Pharma in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Ajanta Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Ajanta Pharma will appreciate offsetting losses from the drop in the long position's value.Ajanta Pharma Pair Trading
Ajanta Pharma Limited Pair Trading Analysis
The ability to find closely correlated positions to Ajanta Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Ajanta Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Ajanta Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Ajanta Pharma Limited to buy it.
The correlation of Ajanta Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Ajanta Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Ajanta Pharma Limited moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Ajanta Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Ajanta Pharma position
In addition to having Ajanta Pharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Utilities ETFs Thematic Idea Now
Utilities ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Utilities ETFs theme has 13 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Utilities ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Ajanta Stock
To fully project Ajanta Pharma's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Ajanta Pharma Limited at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Ajanta Pharma's income statement, its balance sheet, and the statement of cash flows.